Evidence map›Paper›PMID 30420897›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2018

Galangin and Pinocembrin from Propolis Ameliorate Insulin Resistance in HepG2 Cells via Regulating Akt/mTOR Signaling.

Yinkang Liu, Xiali Liang, Gensheng Zhang, Lingjie Kong, Wenjun Peng, Hongcheng Zhang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Frontiers in microbiology · 2025
    Article
  5. Article
  6. Bee (Food science & nutrition · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. A new capacity of gut microbiota: Fermentation of engineered inorganic carbon nanomaterials into endogenous organic metabolites.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  12. Review
  13. Article
  14. A bioactive component ofToxicology research · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yinkang LiuInstitute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China.
Xiali LiangInstitute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China.
Gensheng ZhangCollege of Food Engineering, Harbin University of Commerce, Harbin 150076, China.
Lingjie KongInstitute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China.
Wenjun PengInstitute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China.ORCID 0000-0002-0578-0232
Hongcheng ZhangInstitute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China.ORCID 0000-0003-0232-0107
Chinese Academy of Agricultural Sciences · CNHarbin University of Commerce · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance has a critical role in type 2 diabetes. The aim of this study was to investigate the effect of pinobanksin, galangin, chrysin, and pinocembrin from propolis on insulin resistance. Our study shows that galangin and pinocembrin can ameliorate insulin resistance; on the contrary, pinobanksin and chrysin are ineffective. Galangin and pinocembrin treatments substantially increase glucose consumption and glycogen content by enhancing the activities of hexokinase and pyruvate kinase. Galangin treatment with 80

Identifiers

PMID30420897
PMCPMC6215570
OpenAlexW2897215247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.